Certara, Inc. (NASDAQ:CERT) Given Average Rating of “Hold” by Analysts

Certara, Inc. (NASDAQ:CERT) has been assigned an average rating of “Hold” from the thirteen analysts that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, six have issued a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $8.85.

A number of research firms have weighed in on CERT. Robert W. Baird decreased their price target on Certara from $7.00 to $6.00 and set a “neutral” rating for the company in a report on Tuesday, May 12th. BMO Capital Markets decreased their price target on Certara from $7.00 to $6.00 and set a “market perform” rating for the company in a report on Tuesday, May 12th. Leerink Partners restated an “outperform” rating and issued a $10.00 price target on shares of Certara in a report on Thursday, February 26th. Stephens decreased their price target on shares of Certara from $10.00 to $9.00 and set an “overweight” rating for the company in a research report on Tuesday, May 12th. Finally, TD Cowen reissued a “buy” rating on shares of Certara in a research report on Thursday, February 26th.

Institutional Investors Weigh In On Certara

Hedge funds and other institutional investors have recently modified their holdings of the stock. Wasatch Advisors LP increased its stake in Certara by 28.6% in the 3rd quarter. Wasatch Advisors LP now owns 17,398,337 shares of the company’s stock worth $212,608,000 after purchasing an additional 3,865,455 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in Certara by 2.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 8,562,508 shares of the company’s stock valued at $48,806,000 after acquiring an additional 175,024 shares in the last quarter. Deerfield Management Company L.P. grew its stake in Certara by 71.7% during the 3rd quarter. Deerfield Management Company L.P. now owns 6,739,537 shares of the company’s stock valued at $82,357,000 after acquiring an additional 2,813,438 shares in the last quarter. Geneva Capital Management LLC grew its stake in Certara by 0.7% during the 3rd quarter. Geneva Capital Management LLC now owns 6,160,754 shares of the company’s stock valued at $75,284,000 after acquiring an additional 45,859 shares in the last quarter. Finally, Ameriprise Financial Inc. grew its stake in Certara by 27.1% during the 2nd quarter. Ameriprise Financial Inc. now owns 5,460,630 shares of the company’s stock valued at $63,889,000 after acquiring an additional 1,165,064 shares in the last quarter. 73.96% of the stock is currently owned by institutional investors.

Certara Price Performance

Shares of NASDAQ CERT opened at $5.24 on Friday. The firm has a market capitalization of $815.19 million, a P/E ratio of -52.40 and a beta of 1.53. Certara has a one year low of $4.45 and a one year high of $13.88. The company’s fifty day moving average is $5.80 and its two-hundred day moving average is $7.58. The company has a debt-to-equity ratio of 0.28, a quick ratio of 1.88 and a current ratio of 1.88.

Certara (NASDAQ:CERT) last released its earnings results on Monday, May 11th. The company reported $0.09 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). Certara had a negative net margin of 3.60% and a positive return on equity of 3.52%. The firm had revenue of $106.92 million during the quarter, compared to analysts’ expectations of $106.13 million. During the same quarter last year, the company posted $0.14 earnings per share. Certara’s revenue for the quarter was up .8% on a year-over-year basis. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. Analysts forecast that Certara will post 0.29 EPS for the current fiscal year.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.